Celgene continues to see positive results for blockbuster hopeful Ozanimod

Celgene ($CELG) says that its blockbuster hopeful Ozanimod continued to score well against a placebo arm during the maintenance phase of a trial for ulcerative colitis. The 103 patients who had achieved a clinical response after 8 weeks of therapy continued treatment for an added 24 weeks, and 21% in the 1-mg drug arm achieved or maintain remission at 32 weeks--compared to 6% in the placebo arm. Celgene acquired Ozanimod in its $7.2 billion Receptos buyout last July. The Phase III program is expected to read out in 2017, setting up what Celgene hopes will be an approval for a drug that could earn up to $6 billion a year. Release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.